ELANElanco Animal Health Incorporated

$12B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.2B-8.1% YoY

Gross Profit

$558M47.5% margin

Operating Income

$133M11.3% margin

Net Income

-$10M-0.9% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-4.2%

Cash Flow

Operating Cash Flow

$312M

Free Cash Flow

$279M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$15.6B

Total Liabilities

$8.5B

Stockholders' Equity

$7.1B

Cash & Equivalents

$507M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.3B	-8.1%
Gross Profit	$558M	$599M	-6.8%
Operating Income	$133M	$120M	+10.8%
Net Income	-$10M	-$210M	+95.2%

Revenue Segments

Pet Health

$612M36%

Farm Animal

$553M33%

Cattle

$248M15%

Poultry

$174M10%

Swine

$89M5%

Contract Manufacturing

$12M1%

Geographic Segments

Non-US

$638M54%

UNITED STATES

$539M46%

ELAN Q2 2022 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena